BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 38520605)

  • 1. Pioneering the Way: The Revolutionary Potential of Antibody-Drug Conjugates in NSCLC.
    Chen X; Zeng C
    Curr Treat Options Oncol; 2024 Apr; 25(4):556-584. PubMed ID: 38520605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
    Abuhelwa Z; Alloghbi A; Nagasaka M
    Cancer Treat Rev; 2022 May; 106():102393. PubMed ID: 35472631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
    Verma S; Breadner D; Raphael J
    Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.
    Reuss JE; Gosa L; Liu SV
    Clin Lung Cancer; 2021 Nov; 22(6):483-499. PubMed ID: 34420859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
    Parisi C; Mahjoubi L; Gazzah A; Barlesi F
    Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.
    Marks JA; Wilgucki M; Liu SV; Reuss JE
    Curr Oncol Rep; 2022 Dec; 24(12):1829-1841. PubMed ID: 36197593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
    Liu X; Deng J; Zhang R; Xing J; Wu Y; Chen W; Liang B; Xing D; Xu J; Zhang M
    Front Immunol; 2023; 14():1335252. PubMed ID: 38162667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
    Marks S; Naidoo J
    Lung Cancer; 2022 Jan; 163():59-68. PubMed ID: 34923203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?
    Reuss JE; Rosner S; Levy BP
    Clin Adv Hematol Oncol; 2024 Jun; 22(5):217-226. PubMed ID: 38805313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer.
    Huhe M; Lou J; Zhu Y; Zhao Y; Shi Y; Wang B; Sun X; Zhang X; Zhang Y; Chen ZN
    Biochem Biophys Res Commun; 2019 Jun; 513(4):1083-1091. PubMed ID: 31010682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer].
    Wang N; Zhao L; Zhang D; Jia Y; Kong F
    Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):214-218. PubMed ID: 35340165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
    Desai A; Abdayem P; Adjei AA; Planchard D
    Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer.
    Salifu I; Singh N; Berraondo M; Remon J; Salifu S; Severson E; Quintana A; Peiró S; Ramkissoon S; Vidal L; Chico I; Saini KS
    Cancer Treat Res Commun; 2023; 36():100713. PubMed ID: 37172552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody drug conjugates in thoracic malignancies.
    Pacheco JM; Camidge DR
    Lung Cancer; 2018 Oct; 124():260-269. PubMed ID: 30268471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
    Koopman LA; Terp MG; Zom GG; Janmaat ML; Jacobsen K; Gresnigt-van den Heuvel E; Brandhorst M; Forssmann U; de Bree F; Pencheva N; Lingnau A; Zipeto MA; Parren PW; Breij EC; Ditzel HJ
    JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31600169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapeutic agents for advanced non-small cell lung cancer.
    Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
    J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.
    Passaro A; Jänne PA; Peters S
    J Clin Oncol; 2023 Jul; 41(21):3747-3761. PubMed ID: 37224424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting a Radiosensitizing Antibody-Drug Conjugate to a Radiation-Inducible Antigen.
    Lewis CD; Singh AK; Hsu FF; Thotala D; Hallahan DE; Kapoor V
    Clin Cancer Res; 2021 Jun; 27(11):3224-3233. PubMed ID: 34074654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.